Dr. Romeo Ang Mandanas, MD

Dr. Mandanas practices at INTEGRIS Health Baptist Medical Center in Oklahoma City, Oklahoma, part of INTEGRIS Health.

Dr. Mandanas' NPI, 1114974466, was assigned on May 30, 2006. Dr. Mandanas holds Oklahoma license 18541.

Dr. Mandanas' primary practice is INTEGRIS Health Baptist Medical Center, at 3300 Northwest Expressway, Oklahoma City, OK 73112 in Oklahoma County. The practice phone is (405) 949-3011.

Dr. Mandanas' primary practice is INTEGRIS Health Baptist Medical Center in Oklahoma City, Oklahoma, part of INTEGRIS Health. Dr. Mandanas is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is INTEGRIS Health Medical Group. Dmand AI also links Dr. Mandanas to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mandanas practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mandanas' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mandanas is licensed in Oklahoma.

CMS data shows 1,135 Medicare services from Dr. Mandanas across 4 procedure codes in 2024, for 397 Medicare patients. Medicare paid $81,269 for them.

CMS counts 397 Medicare patients who saw Dr. Mandanas in 2024. The largest group is 65 to 74, with 170 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mandanas' median patient age at 69, with 54% women.

In 2024, Dr. Mandanas wrote 1,529 Medicare Part D claims for 195 patients. 73% of them were for generic drugs. CMS names the drug for 1,286 of them, across 50 drugs with 11 or more claims each, at $3,541,605 in total drug cost. In 2023, CMS named 993 claims across 42 drugs.

Dr. Mandanas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Dr. Mandanas, published from 2010 to 2013. Dr. Mandanas' most frequent co-authors are Roy A. Beveridge, MD, Philip D. Bonomi, MD and Andrew R. Greenspan, MD.

Dmand AI links Dr. Mandanas to 1 clinical trial. Conditions studied include Carcinoma, Renal Cell and Kidney Neoplasms.

CMS Open Payments shows 517 general payments to Dr. Mandanas from 41 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Celgene Corporation paid the most, $105,661.